Pentoxifylline Treatment of Acute Pancreatitis

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis, to see if it can improve blood tests associated with inflammation (tissue damage). Pentoxifylline is approved by the US Food and Drug Administration (FDA) for treatment of circulation problems, but its use in this study is investigational, which means that the FDA has not approved it for the treatment of pancreatitis. However, the FDA has allowed the use of pentoxifylline in this research study.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

1. Predicted Severe Acute Pancreatitis

2. Enrollment within 72 hours of diagnosis

3. Ability to give informed consent

4. Age >17 years

Exclusion Criteria:

1. Moderate or severe congestive heart failure

2. History of seizure disorder or demyelinating disease

3. Nursing mothers

4. Pregnancy

5. History of prior tuberculosis or risk factors for tuberculosis

6. Evidence of immunosuppression (malignancy, chronic renal failure, chemotherapy within 60 days, ongoing steroid treatment*, and HIV)- (*the exception of prednisone use will be allowed to participate).

7. Evidence of chronic pancreatitis from history and examination (however, "acute on chronic pancreatitis" diagnosis is allowed)

8. Evidence of active or pending hemorrhage.

9. Paralytic ileus with vomiting